What hormone replacement therapy regimen is recommended for a generally healthy menopausal woman experiencing moderate to severe vasomotor symptoms?

Hormone Replacement Therapy for Menopausal Vasomotor Symptoms

For a generally healthy menopausal woman under age 60 or within 10 years of menopause onset experiencing moderate to severe vasomotor symptoms, initiate systemic estrogen therapy (with progestogen if she has a uterus), as this is the most effective treatment with benefits exceeding risks in this population 1, 2.

Treatment Algorithm

First-Line: Systemic Hormone Therapy

Estrogen Selection:

• Oral estrogen (conjugated equine estrogens or 17β-estradiol) OR transdermal estradiol - both have similar efficacy, reducing vasomotor symptoms by approximately 75% 3
• Use the lowest effective dose: Start with ultra-low dose formulations (e.g., 0.5 mg 17β-estradiol) which are as effective as standard doses but with better tolerability 4
• Transdermal formulations may be preferable as they do not increase venous thromboembolism risk unlike oral formulations 5

Progestogen Addition (if uterus present):

• Add progestogen to prevent endometrial hyperplasia 1
• Micronized progesterone or dydrogesterone preferred - do not increase VTE risk 5
• Avoid medroxyprogesterone acetate when possible due to higher breast cancer risk with combination therapy 2

Specific Regimen Options:

• 0.5 mg 17β-estradiol + 2.5 mg dydrogesterone: Reduces hot flashes by 6.4/day, 81-91% amenorrhea rate, excellent tolerability 4
• Low-dose conjugated equine estrogens + bazedoxifene: No increased breast cancer risk (0.25%/year vs 0.23%/year placebo) 3
• Drospirenone 0.5 mg + estradiol 0.5 mg: Most effective for symptom severity reduction 6

Critical Screening Before Initiation

Absolute contraindications 2:

• Current/past breast cancer or estrogen-sensitive malignancy
• Undiagnosed vaginal bleeding
• Active/recent arterial thromboembolism (MI, angina)
• Previous idiopathic VTE
• Active liver disease
• Untreated endometrial hyperplasia
• Untreated hypertension

Risk assessment required 2:

• Cardiovascular risk factors (lipids, smoking, diabetes, family history)
• Breast cancer risk
• VTE risk factors

Duration and Monitoring

• Short-term use recommended: 4-5 years maximum for most women, as breast cancer risk increases with longer duration 7
• The "timing hypothesis" is critical: Benefits exceed risks when initiated before age 60 or within 10 years of menopause onset 1, 5
• Initiation many years after menopause increases coronary risk 7

Alternative Options (Second-Line)

If hormone therapy contraindicated or declined 3, 7:

• Fezolinetant or elinzanetant (newer non-hormonal options): Moderate efficacy, reducing symptoms by 40-65% 6
• SSRIs/SNRIs: Paroxetine, venlafaxine, escitalopram, citalopram, desvenlafaxine - reduce symptoms by 40-65% 3
• Gabapentin: Effective alternative 7

Key Safety Considerations

Absolute risks are small 3:

• Stroke and VTE with oral conjugated equine estrogens: ~1 excess event per 1,000 person-years
• Breast cancer with estrogen + medroxyprogesterone: ~1 excess event per 1,000 person-years
• These risks are age-dependent and increase after age 60 2

Not indicated for 1, 2:

• Primary/secondary cardiovascular disease prevention
• Dementia prevention
• Breast cancer prevention

Common Pitfalls to Avoid

1. Don't delay treatment in appropriate candidates - the timing window matters for cardiovascular safety 5
2. Don't use oral estrogen in women with VTE risk factors - switch to transdermal 5
3. Don't prescribe without progestogen in women with intact uterus 1
4. Don't continue indefinitely without reassessment - attempt discontinuation after 4-5 years 7
5. Don't use for prevention of chronic diseases - only for symptom management 1, 3